ERBB2 and neoplasm: Fifty patients (81%) were diagnosed with a hormone receptor (HR) + /HER2-negative tumor, six cases (10%) with had immunohistochemistry staining indicating HR + /HER2 + tumor as evaluated by immunhistochemistry, and five patients (8%) had a TNBC (Table 1).